Serum Cartilage Oligomeric Matrix Protein and Golgi Protein-73: New Diagnostic and Predictive Tools for Liver Fibrosis and Hepatocellular Cancer?
Abstract
:Simple Summary
Abstract
1. Introduction
2. Material and Methods
Statistical Analysis
3. Results
3.1. Significance of Dual Positivity for GP73 and COMP in Relation to the Baseline Characteristics of Patients
3.2. Dual Positivity for GP73 and COMP as a Diagnostic Marker of Significant Fibrosis and Cirrhosis
3.3. Combination of GP73 and COMP as Predictive Marker of Outcome
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Singal, A.G.; Lampertico, P.; Nahon, P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J. Hepatol. 2020, 72, 250–261. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kulik, L.; El-Serag, H.B. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology 2019, 156, 477–491.e471. [Google Scholar] [CrossRef]
- Villanueva, A. Hepatocellular Carcinoma. N. Engl. J. Med. 2019, 380, 1450–1462. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2018, 69, 182–236. [Google Scholar] [CrossRef] [Green Version]
- Marrero, J.A.; Kulik, L.M.; Sirlin, C.B.; Zhu, A.X.; Finn, R.S.; Abecassis, M.M.; Roberts, L.R.; Heimbach, J.K. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018, 68, 723–750. [Google Scholar] [CrossRef] [Green Version]
- European Association for Study of the Liver. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J. Hepatol. 2015, 63, 237–264. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Murillo Perez, C.F.; Hirschfield, G.M.; Corpechot, C.; Floreani, A.; Mayo, M.J.; van der Meer, A.; Ponsioen, C.Y.; Lammers, W.J.; Parés, A.; Invernizzi, P.; et al. Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. Aliment. Pharmacol. Ther. 2019, 50, 1127–1136. [Google Scholar] [CrossRef]
- Raoul, J.L.; Kudo, M.; Finn, R.S.; Edeline, J.; Reig, M.; Galle, P.R. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treat Rev. 2018, 68, 16–24. [Google Scholar] [CrossRef] [Green Version]
- Rockey, D.C.; Caldwell, S.H.; Goodman, Z.D.; Nelson, R.C.; Smith, A.D.; American Association for the Study of Liver Diseases. Liver biopsy. Hepatology 2009, 49, 1017–1044. [Google Scholar] [CrossRef]
- Bedossa, P.; Carrat, F. Liver biopsy: The best, not the gold standard. J. Hepatol. 2009, 50, 1–3. [Google Scholar] [CrossRef] [Green Version]
- Wai, C.T.; Greenson, J.K.; Fontana, R.J.; Kalbfleisch, J.D.; Marrero, J.A.; Conjeevaram, H.S.; Lok, A.S. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38, 518–526. [Google Scholar] [CrossRef] [Green Version]
- Sterling, R.K.; Lissen, E.; Clumeck, N.; Sola, R.; Correa, M.C.; Montaner, J.; Sulkowski, M.S.; Torriani, F.J.; Dieterich, D.T.; Thomas, D.L.; et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006, 43, 1317–1325. [Google Scholar] [CrossRef] [PubMed]
- Sandrin, L.; Fourquet, B.; Hasquenoph, J.M.; Yon, S.; Fournier, C.; Mal, F.; Christidis, C.; Ziol, M.; Poulet, B.; Kazemi, F.; et al. Transient elastography: A new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med. Biol. 2003, 29, 1705–1713. [Google Scholar] [CrossRef]
- Zachou, K.; Lygoura, V.; Arvaniti, P.; Giannoulis, G.; Gatselis, N.K.; Koukoulis, G.K.; Dalekos, G.N. FibroMeter scores for the assessment of liver fibrosis in patients with autoimmune liver diseases. Ann. Hepatol. 2021, 22, 100285. [Google Scholar] [CrossRef] [PubMed]
- Ocker, M. Biomarkers for hepatocellular carcinoma: What’s new on the horizon? World J. Gastroenterol. 2018, 24, 3974–3979. [Google Scholar] [CrossRef] [PubMed]
- Gatselis, N.K.; Tornai, T.; Shums, Z.; Zachou, K.; Saitis, A.; Gabeta, S.; Albesa, R.; Norman, G.L.; Papp, M.; Dalekos, G.N. Golgi protein-73: A biomarker for assessing cirrhosis and prognosis of liver disease patients. World J. Gastroenterol. 2020, 26, 5130–5145. [Google Scholar] [CrossRef] [PubMed]
- Norman, G.L.; Gatselis, N.K.; Shums, Z.; Liaskos, C.; Bogdanos, D.P.; Koukoulis, G.K.; Dalekos, G.N. Cartilage oligomeric matrix protein: A novel non-invasive marker for assessing cirrhosis and risk of hepatocellular carcinoma. World J. Hepatol. 2015, 7, 1875–1883. [Google Scholar] [CrossRef]
- Zachou, K.; Gabeta, S.; Shums, Z.; Gatselis, N.K.; Koukoulis, G.K.; Norman, G.L.; Dalekos, G.N. COMP serum levels: A new non-invasive biomarker of liver fibrosis in patients with chronic viral hepatitis. Eur. J. Intern. Med. 2017, 38, 83–88. [Google Scholar] [CrossRef]
- Zachou, K.; Gabeta, S.; Gatselis, N.K.; Norman, G.L.; Dalekos, G.N. Cartilage oligomeric matrix protein on the spot for liver fibrosis evaluation: Too early or too late? Eur. J. Intern. Med. 2017, 43, e48–e49. [Google Scholar] [CrossRef]
- Cao, Z.; Li, Z.; Wang, Y.; Liu, Y.; Mo, R.; Ren, P.; Chen, L.; Lu, J.; Li, H.; Zhuang, Y.; et al. Assessment of serum Golgi protein 73 as a biomarker for the diagnosis of significant fibrosis in patients with chronic HBV infection. J. Viral. Hepat. 2017, 24 (Suppl. 1), 57–65. [Google Scholar] [CrossRef]
- Wang, L.; Yao, M.; Liu, S.; Yang, D.; Wen, X.; Ning, J.; Wang, L.; Zhou, G.; Xu, Q.; Chen, X.; et al. Serum Golgi Protein 73 as a Potential Biomarker for Hepatic Necroinflammation in Population with Nonalcoholic Steatohepatitis. Dis. Markers 2020, 2020, 6036904. [Google Scholar] [CrossRef] [PubMed]
- Xia, Y.; Zhang, Y.; Shen, M.; Xu, H.; Li, Z.; He, N. Golgi protein 73 and its diagnostic value in liver diseases. Cell Prolif. 2019, 52, e12538. [Google Scholar] [CrossRef] [PubMed]
- Magdaleno, F.; Arriazu, E.; Ruiz de Galarreta, M.; Chen, Y.; Ge, X.; Conde de la Rosa, L.; Nieto, N. Cartilage oligomeric matrix protein participates in the pathogenesis of liver fibrosis. J. Hepatol. 2016, 65, 963–971. [Google Scholar] [CrossRef] [Green Version]
- Andreasson, K.; Hesselstrand, R.; Saxne, T.; Holmberg, A.; Norrgren, H.; Jonsson, G. Cartilage oligomeric matrix protein: A new promising biomarker of liver fibrosis in chronic hepatitis C. Infect. Dis. 2015, 47, 915–918. [Google Scholar] [CrossRef]
- Xiao, Y.; Kleeff, J.; Guo, J.; Gazdhar, A.; Liao, Q.; Di Cesare, P.E.; Buchler, M.W.; Friess, H. Cartilage oligomeric matrix protein expression in hepatocellular carcinoma and the cirrhotic liver. J. Gastroenterol. Hepatol. 2004, 19, 296–302. [Google Scholar] [CrossRef]
- Munro, S. Localization of proteins to the Golgi apparatus. Trends Cell Biol. 1998, 8, 11–15. [Google Scholar] [CrossRef]
- Kladney, R.D.; Bulla, G.A.; Guo, L.; Mason, A.L.; Tollefson, A.E.; Simon, D.J.; Koutoubi, Z.; Fimmel, C.J. GP73, a novel Golgi-localized protein upregulated by viral infection. Gene 2000, 249, 53–65. [Google Scholar] [CrossRef]
- Kim, H.J.; Lv, D.; Zhang, Y.; Peng, T.; Ma, X. Golgi phosphoprotein 2 in physiology and in diseases. Cell Biosci. 2012, 2, 31. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Papatheodoridis, G.V.; Sypsa, V.; Dalekos, G.N.; Yurdaydin, C.; Van Boemmel, F.; Buti, M.; Calleja, J.L.; Chi, H.; Goulis, J.; Manolakopoulos, S.; et al. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. J. Hepatol. 2020, 72, 1088–1096. [Google Scholar] [CrossRef] [PubMed]
- Dalekos, G.N.; Azariadis, K.; Lygoura, V.; Arvaniti, P.; Gampeta, S.; Gatselis, N.K. Autoimmune hepatitis in patients aged 70 years or older: Disease characteristics, treatment response and outcome. Liver Int. 2021. [Google Scholar] [CrossRef]
- Bedossa, P.; Poynard, T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24, 289–293. [Google Scholar] [CrossRef] [PubMed]
- Castera, L.; Vergniol, J.; Foucher, J.; Le Bail, B.; Chanteloup, E.; Haaser, M.; Darriet, M.; Couzigou, P.; De Ledinghen, V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128, 343–350. [Google Scholar] [CrossRef] [PubMed]
- Younossi, Z.M.; Stepanova, M.; Rafiq, N.; Makhlouf, H.; Younoszai, Z.; Agrawal, R.; Goodman, Z. Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011, 53, 1874–1882. [Google Scholar] [CrossRef] [PubMed]
- Lin, Z.H.; Xin, Y.N.; Dong, Q.J.; Wang, Q.; Jiang, X.J.; Zhan, S.H.; Sun, Y.; Xuan, S.Y. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: An updated meta-analysis. Hepatology 2011, 53, 726–736. [Google Scholar] [CrossRef] [PubMed]
- Xiao, G.; Yang, J.; Yan, L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: A systemic review and meta-analysis. Hepatology 2015, 61, 292–302. [Google Scholar] [CrossRef]
- Liu, X.; Wan, X.; Li, Z.; Lin, C.; Zhan, Y.; Lu, X. Golgi protein 73(GP73), a useful serum marker in liver diseases. Clin. Chem. Lab. Med. 2011, 49, 1311–1316. [Google Scholar] [CrossRef]
- Yao, M.; Wang, L.; Leung, P.S.C.; Li, Y.; Liu, S.; Wang, L.; Guo, X.; Zhou, G.; Yan, Y.; Guan, G.; et al. The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review. Clin. Rev. Allergy Immunol. 2018, 54, 282–294. [Google Scholar] [CrossRef]
- Iftikhar, R.; Kladney, R.D.; Havlioglu, N.; Schmitt-Graff, A.; Gusmirovic, I.; Solomon, H.; Luxon, B.A.; Bacon, B.R.; Fimmel, C.J. Disease- and cell-specific expression of GP73 in human liver disease. Am. J. Gastroenterol. 2004, 99, 1087–1095. [Google Scholar] [CrossRef]
- Kladney, R.D.; Cui, X.; Bulla, G.A.; Brunt, E.M.; Fimmel, C.J. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology 2002, 35, 1431–1440. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Xu, Z.; Shen, J.; Pan, X.; Wei, M.; Liu, L.; Wei, K.; Liu, L.; Yang, H.; Huang, J. Predictive value of serum Golgi protein 73 for prominent hepatic necroinflammation in chronic HBV infection. J. Med. Virol. 2018, 90, 1053–1062. [Google Scholar] [CrossRef]
- Liu, T.; Yao, M.; Liu, S.; Wang, L.; Wang, L.; Hou, J.; Ma, X.; Jia, J.; Zhao, J.; Zhuang, H.; et al. Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma. Oncotarget 2017, 8, 16498–16506. [Google Scholar] [CrossRef] [PubMed]
- Morota, K.; Nakagawa, M.; Sekiya, R.; Hemken, P.M.; Sokoll, L.J.; Elliott, D.; Chan, D.W.; Dowell, B.L. A comparative evaluation of Golgi protein-73, fucosylated hemopexin, alpha-fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Clin. Chem. Lab. Med. 2011, 49, 711–718. [Google Scholar] [CrossRef]
- Qiao, Y.; Chen, J.; Li, X.; Wei, H.; Xiao, F.; Chang, L.; Zhang, R.; Hao, X.; Wei, H. Serum gp73 is also a biomarker for diagnosing cirrhosis in population with chronic HBV infection. Clin. Biochem. 2014, 47, 216–222. [Google Scholar] [CrossRef]
- Wei, H.; Zhang, J.; Li, H.; Ren, H.; Hao, X.; Huang, Y. GP73, a new marker for diagnosing HBV-ACLF in population with chronic HBV infections. Diagn. Microbiol. Infect. Dis. 2014, 79, 19–24. [Google Scholar] [CrossRef] [PubMed]
- Qian, X.; Zheng, S.; Wang, L.; Yao, M.; Guan, G.; Wen, X.; Zhang, L.; Xu, Q.; Chen, X.; Zhao, J.; et al. Exploring the Diagnostic Potential of Serum Golgi Protein 73 for Hepatic Necroinflammation and Fibrosis in Chronic HCV Infection with Different Stages of Liver Injuries. Dis. Markers 2019, 2019, 3862024. [Google Scholar] [CrossRef] [Green Version]
- Cao, Z.; Li, Z.; Wang, H.; Liu, Y.; Xu, Y.; Mo, R.; Ren, P.; Chen, L.; Lu, J.; Li, H.; et al. Algorithm of Golgi protein 73 and liver stiffness accurately diagnoses significant fibrosis in chronic HBV infection. Liver Int. 2017, 37, 1612–1621. [Google Scholar] [CrossRef] [PubMed]
- Hedbom, E.; Antonsson, P.; Hjerpe, A.; Aeschlimann, D.; Paulsson, M.; Rosa-Pimentel, E.; Sommarin, Y.; Wendel, M.; Oldberg, A.; Heinegard, D. Cartilage matrix proteins. An acidic oligomeric protein (COMP) detected only in cartilage. J. Biol. Chem. 1992, 267, 6132–6136. [Google Scholar] [CrossRef]
- Skoumal, M.; Haberhauer, G.; Feyertag, J.; Kittl, E.M.; Bauer, K.; Dunky, A. Serum levels of cartilage oligomeric matrix protein (COMP): A rapid decrease in patients with active rheumatoid arthritis undergoing intravenous steroid treatment. Rheumatol. Int. 2006, 26, 1001–1004. [Google Scholar] [CrossRef]
- Tseng, S.; Reddi, A.H.; Di Cesare, P.E. Cartilage Oligomeric Matrix Protein (COMP): A Biomarker of Arthritis. Biomark. Insights 2009, 4, 33–44. [Google Scholar] [CrossRef] [PubMed]
- Chin, J.L.; Pavlides, M.; Moolla, A.; Ryan, J.D. Non-invasive markers of liver fibrosis: Adjuncts or alternatives to liver biopsy? Front. Pharmacol. 2016, 7, 159. [Google Scholar] [CrossRef] [Green Version]
- Piñero, F.; Dirchwolf, M.; Pessôa, M.G. Biomarkers in hepatocellular carcinoma: Diagnosis, prognosis and treatment response assessment. Cells 2020, 9, 1370. [Google Scholar] [CrossRef] [PubMed]
- Eilard, S.E.; Aberg, F. Combination of biomarkers for the detection of hepatocellular carcinoma. Ann. Transl. Med. 2020, 8, 1283. [Google Scholar] [CrossRef]
- Sebastiani, G.; Halfon, P.; Castera, L.; Pol, S.; Thomas, D.L.; Mangia, A.; Di Marco, V.; Pirisi, M.; Voiculescu, M.; Guido, M.; et al. SAFE biopsy: A validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology 2009, 6, 1821–1827. [Google Scholar] [CrossRef] [PubMed]
- Zhao, S.; Long, M.; Zhang, X.; Lei, S.; Dou, W.; Hu, J.; Du, X.; Liu, L. The diagnostic value of the combination of Golgi-protein 73, glypican-3 and alpha-fetoprotein in hepatocellular carcinoma: A diagnostic meta-analysis. Ann. Transl. Med. 2020, 8, 536. [Google Scholar] [CrossRef] [PubMed]
- Leroy, V.; Sturm, N.; Faure, P.; Trocme, C.; Marlu, A.; Hilleret, M.N.; Morel, F.; Zarski, J.P. Prospective evaluation of FibroTest(R), FibroMeter(R), and HepaScore(R) for staging liver fibrosis in chronic hepatitis B: Comparison with hepatitis C. J. Hepatol. 2014, 61, 28–34. [Google Scholar] [CrossRef] [PubMed]
Baseline Characteristics | Total Cohort (n = 288) |
---|---|
Age, median (IQR), years | 53 (25) |
Sex, male/female, n (%) | 161/127 (55.9%/44.1%) |
CHB/CHC/Alcoholic/PBC/AIH, n | 129/120/12/21/6 |
GP73, median (IQR), units, (ULN: 20 units) | 10.4 (9) |
GP73, pos/neg, n (%) | 54/234 (18.8%/81.3%) |
COMP, median (IQR), units, (ULN: 15 U/L) | 10.3 (6) |
COMP, pos/neg, n (%) | 61/227 (21.2%/78.8%) |
INR, median (IQR), (normal: 0.85–1.15) | 1.04 (0.17) |
Platelets, median (IQR), ×103/μL (normal: 140–440) | 190 (100) |
AST, median (IQR), (ULN: 40 U/L) | 35 (40) |
ALT, median (IQR), (ULN: 40 U/L) | 39 (44) |
γ-GT, median (IQR), (ULN: 37 U/L) | 32 (52) |
ALP, median (IQR), (ULN: 104 U/L) | 81 (60) |
Bilirubin, median (IQR), (ULN: 1.1 mg/dL) | 0.8 (0.7) |
Albumin, median (IQR), (normal: 3.5–5.2 g/dL) | 4.4 (0.8) |
AFP, median (IQR), (ULN: 10 ng/mL) | 3.4 (4.5) |
APRI | 0.5 (0.7) |
FIB-4 | 1.5 (2) |
METAVIR F1/F2/F3/F4, n (%) * | 63/44/20/50 (35.6%/24.9%/11.3%/28.2%) |
Baseline cirrhosis, n (%) | 116/288 (40.3%) |
Baseline decompensation of cirrhosis, n (%) | 33/116 (28.4%) |
Baseline HCC, n (%) | 12/288 (4.2%) |
Follow-up ≥ 6 months, yes/no, n (%) | 236/52 (81.9%/18.1%) |
Duration of follow-up, median (IQR), months | 98 (92) |
Baseline Characteristics | GP73 Pos./COMP Pos. (n = 24) | GP73 Pos./COMP Neg. (n = 30) | GP73 Neg./COMP Pos. (n = 37) | GP73 Neg./COMP Neg. (n = 197) | P-Value |
---|---|---|---|---|---|
Age, median (IQR), years | 65 (13) | 55 (26) | 58 (21) | 51 (23) | <0.001 |
INR, median (IQR), (normal: 0.85–1.15) | 1.25 (0.28) | 1.21 (0.44) | 1.09 (0.22) | 1.01 (0.11) | <0.001 |
Platelets, median (IQR), ×103/μL (normal: 140–440) | 87 (67) | 154 (96) | 185 (110) | 199 (79) | <0.001 |
AST, median (IQR), (ULN: 40 U/L) | 91 (90) | 42 (51) | 38 (39) | 28 (29) | <0.001 |
ALT, median (IQR), (ULN: 40 U/L) | 72 (88) | 43 (60) | 35 (32) | 37 (41) | <0.001 |
γ-GT, median (IQR), (ULN: 37 U/L) | 61 (86) | 47 (112) | 36 (44) | 27 (45) | <0.001 |
ALP, median (IQR), (ULN: 104 U/L) | 144 (111) | 90 (62) | 93 (63) | 72 (57) | <0.001 |
Bilirubin, median (IQR), (ULN: 1.1 mg/dL) | 1.9 (3.2) | 1 (1.4) | 0.8 (0.8) | 0.7 (0.6) | <0.001 |
Albumin, median (IQR), (normal: 3.5–5.2 g/dL) | 3.5 (1.1) | 3.8 (0.9) | 4.3 (1) | 4.5 (0.6) | <0.001 |
AFP, median (IQR), (ULN: 10 ng/mL) | 9.9 (20.4) | 4.3 (10.8) | 4.8 (6) | 3 (3) | <0.001 |
APRI | 2.7 (3.8) | 0.8 (1.2) | 0.6 (0.6) | 0.4 (0.5) | <0.001 |
FIB-4 | 8.3 (6.3) | 3.4 (3.8) | 2.1 (2.1) | 1.3 (1.2) | <0.001 |
METAVIR F2-F3-F4/F1, n (%) * | 8 (100%)/0 (0%) | 14 (93.3%)/1 (6.7%) | 16 (94.1%)/1 (5.9%) | 76 (55%)/61 (44%) | <0.001 |
Baseline cirrhosis, n (%) | 23 (95.8%) | 22 (73.3%) | 25 (67.6%) | 46 (23.4%) | <0.001 |
Baseline decompensation of cirrhosis #, n (%) | 9 (39.1%) | 11 (50%) | 5 (20%) | 8 (17.4%) | 0.019 |
Baseline HCC, n (%) | 2 (8.3%) | 3 (10%) | 4 (10.8%) | 3 (1.5%) | 0.011 |
Baseline Factors | Univariate Analysis | Multivariate Analysis | ||||
---|---|---|---|---|---|---|
HR | 95% CI | P-Value | HR | 95% CI | P-Value | |
COMP + GP73 | 39.81 | 12.60–125.7 | <0.001 | 13.55 | 3.616–50.78 | <0.001 |
Age | 1.106 | 1.066–1.148 | <0.001 | 1.079 | 1.038–1.122 | <0.001 |
Male sex | 3.168 | 1.368–7.337 | 0.007 | 3.134 | 1.338–7.340 | 0.009 |
Platelets | 0.033 | 0.008–0.130 | <0.001 | 19.78 | 0.749–522.6 | ns |
AFP | 0.999 | 0.990–1.008 | 0.814 | na | na | na |
FIB-4 | 1.286 | 1.206–1.372 | <0.001 | 1.302 | 1.089–1.557 | 0.004 |
Viral vs. non-viral liver disease | 1.595 | 0.483–5.265 | 0.443 | na | na | na |
Baseline Factors | Univariate Analysis | Multivariate Analysis | ||||
---|---|---|---|---|---|---|
HR | 95% CI | P-Value | HR | 95% CI | P-Value | |
COMP + GP73 | 62.48 | 22.01–177.3 | <0.001 | 23.11 | 6.972–76.58 | <0.001 |
Age | 1.081 | 1.051–1.113 | 0.001 | 1.044 | 1.014–1.076 | 0.004 |
Male sex | 1.539 | 0.835–2.837 | 0.167 | na | na | na |
Platelets | 0.035 | 0.011–0.108 | <0.001 | 0.817 | 0.078–8.559 | 0.866 |
FIB-4 | 1.228 | 1.165–1.294 | <0.001 | 1.073 | 0.944–1.220 | 0.134 |
Viral vs. non-viral liver disease | 0.434 | 0.223–0.844 | 0.014 | 1.073 | 0.944–1.220 | 0.280 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gatselis, N.K.; Zachou, K.; Giannoulis, G.; Gabeta, S.; Norman, G.L.; Dalekos, G.N. Serum Cartilage Oligomeric Matrix Protein and Golgi Protein-73: New Diagnostic and Predictive Tools for Liver Fibrosis and Hepatocellular Cancer? Cancers 2021, 13, 3510. https://doi.org/10.3390/cancers13143510
Gatselis NK, Zachou K, Giannoulis G, Gabeta S, Norman GL, Dalekos GN. Serum Cartilage Oligomeric Matrix Protein and Golgi Protein-73: New Diagnostic and Predictive Tools for Liver Fibrosis and Hepatocellular Cancer? Cancers. 2021; 13(14):3510. https://doi.org/10.3390/cancers13143510
Chicago/Turabian StyleGatselis, Nikolaos K., Kalliopi Zachou, George Giannoulis, Stella Gabeta, Gary L. Norman, and George N. Dalekos. 2021. "Serum Cartilage Oligomeric Matrix Protein and Golgi Protein-73: New Diagnostic and Predictive Tools for Liver Fibrosis and Hepatocellular Cancer?" Cancers 13, no. 14: 3510. https://doi.org/10.3390/cancers13143510